Patheon Inc

Patheon — Q3 2006 Earnings Presentation

11 slides from Patheon's earnings presentation, Sep 15, 2006

  1. Slide 1: Q3 2006 Financial Results Conference Call

    Q3 2006 FINANCIAL RESULTS CONFERENCE CALL September 15, 2006 10:00 a.m. (EDT) STRATEGIC RELATIONSHIPS | TECHNOLOGIES | PRODUCTS Representing Patheon PETER GREEN Chairman of the Board of Directors RICCARDO TRECROCE Chief Executive Officer NICK DIPIETRO President and Chief Operating Officer NICHOLAS D

  2. Slide 2: Agenda and Forward-looking Information

    Agenda ƒ Overview of Q3 and YTD results (S. Jourard) ƒ Recent developments (R. Trecroce) • MOVA write down • Financing discussions • Strategic review process ƒ Q3 operating performance (N. DiPietro) • North America • Europe ƒ Outlook (R. Trecroce) ƒ Q&A Forward-looking Information This presentation

  3. Slide 3: Q3 2006 and YTD 2006 Highlights

    Q3 2006 Highlights ƒ Revenues up 6% to $189.2M ƒ EBITDA of $16.0M (8.5% of revenues) vs. $25.8M (14.5% of revenues) a year ago ƒ Write down of $254.7M related to MOVA goodwill, tangible and intangible assets ƒ Prior to write down, net loss of $5.1M or 5.5¢ per share vs. net earnings of $3.5M or 3.5¢

  4. Slide 4: Recent Developments: Write Down of Goodwill and Long-lived Assets

    RECENT DEVELOPMENTS Write Down of Goodwill and Long-lived Assets ƒ Recognized a non-cash impairment charge of $254.7M in Q3 • $172.5M goodwill • $66.2M intangibles (values assigned to client contracts) • $15.2M tangibles ƒ Expected earnings from MOVA have not materialized • API shortage for Omnicef

  5. Slide 5: Financing Arrangements and Strategic Alternatives Review

    Financing Arrangements ƒ As announced on July 31, 2006, NA credit agreement was amended and Patheon was compliant with covenants at Q3 2006 ƒ Expecting debt-to-EBITDA levels to exceed covenant tests in Q4 and future periods • As required under GAAP, long-term debt has been reclassifed as current ind

  6. Slide 6: Q3 2006 Overview: Revenues

    OPERATING RESULTS Q3 2006 Overview: Revenues ƒ Revenues up $10.8M or 6% YOY • Canada and Cincinnati commercial manufacturing up 20% • European commercial manufacturing up 9% • Global PDS up 21% • Puerto Rico down 32% Q3 2006 Webcast, Sept 15, 2006 6

  7. Slide 7: Q3 2006 Overview: EBITDA and Puerto Rico Results

    Q3 2006 Overview: EBITDA ƒ EBITDA down $9.8M or 38% YOY • Canada and Cincinnati commercial down 12% • European commercial down 10% • PDS up 38% • Puerto Rico down $8.3M Operating Results: Puerto Rico ƒ EBITDA declined $8.3M, resulting in loss of $3.5M for the Puerto Rico Operations • Caguas signific

  8. Slide 8: Update on Puerto Rico; Canada and Cincinnati Results

    Update on Puerto Rico ƒ Positive results from stability testing of newly packaged product • Shipments resumed Sept. 7th • Supplementary submission filed by client, FDA may respond within 30 days ƒ Omnicef Warning Letter issue resolved • Site regained FDA approval status • Late deliveries eliminated

  9. Slide 9: Operating Results and Update on Europe

    Operating Results: Europe ƒ European commercial manufacturing EBITDA declined by 10% to $8.3M • New business in Italy, offset by declines in mature product volumes at Swindon, U.K. and Bourgoin-Jallieu, France Update on Europe ƒ Transfers of products into Italy, France from client carve-out initiati

  10. Slide 10: Global PDS Operating Results and Update

    Operating Results: Global PDS ƒ Global PDS EBITDA improved 38% to $5.9M • Excellent growth at Cincinnati – new business from specialized capabilities • Strong growth at Swindon – more lab space at Milton Park • Flat revenues and earnings in Canada Update on PDS Preclinical Phase I Phase II Phase III

  11. Slide 11: Outlook

    Outlook ƒ Revenues slightly lower than Q3 • Reduced volumes at Whitby • European summer shut downs • Improved revenues in Puerto Rico Q3 2006 FINANCIAL RESULTS CONFERENCE CALL September 15, 2006 10:00 a.m. (EDT) STRATEGIC RELATIONSHIPS | TECHNOLOGIES | PRODUCTS Q3 2006 Webcast, Sept 15, 2006 11

Patheon — Q3 2006 Earnings Presentation on 6ix